Reporter brief
Fisetin did not improve 6-minute walk distance in peripheral artery disease pilot trial.
What happened
Pilot randomized trial of 34 people with peripheral artery disease assigned to fisetin or placebo. The trial tested whether fisetin would reduce senescent cell markers in blood and tissue and improve 6-minute walk distance. The abstract reports the study design and proposed analyses but does not report actual results or whether fisetin affected walking distance, senescent markers, or inflammatory markers.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
People with peripheral artery disease (PAD)
- Design
- Rct
- Sample
- 34
- Journal
- Northwestern University
- Published
- Apr 15, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.